预约演示
更新于：2025-05-07
Ipratropium Bromide
异丙托溴铵
更新于：2025-05-07
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
102
项与 异丙托溴铵 相关的临床试验CTIS2024-514065-19-00
PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT
IRCT20230522058254N1
Evaluation of the effect of ipratropium bromide spray on nasal hypersecretion (rhinorhea) in allergic rhinitis patients
CTR20243249
异丙托溴铵吸入气雾剂治疗慢性阻塞性肺疾病（COPD）的随机、双盲双模拟、单剂量、交叉的药效动力学研究
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,214
项与 异丙托溴铵 相关的文献（医药）2025-03-18Current drug research reviews
Evaluation of Respirable Fraction by using Next Generation Impactor of Levosalbutamol Sulphate and Ipratropium bromide Metered Dose Inhaler
Article
作者: Dhalani, Jayesh ; Chilka, Chirag
Introduction::
A lung condition in which the passage of air into the lungs is obstructed,
is treated using a combination pharmaceutical aerosol (Pressurised Metered dosage Inhaler)
dosage form, such as Levosalbutamol Sulphate (LS) and Ipratropium Bromide (IB) pressurized
inhalation solution, which contains 50 μg and 20 μg, respectively. Aerodynamic particle size
distribution (APSD) aids in comprehending the likelihood of particle deposition in the lungs. In
addition to being crucial for the efficacy and safety of medications, the respirable fraction is a
significant critical quality attribute (CQA) for nasal and orally inhaled medicinal formulations.
Aim::
The evaluation of in-vitro respirable fraction utilizing Next Generator Impactor (NGI)
simulates drug particle deposition in the patient's lungs. The current study used a sensitive highpressure
liquid chromatography technique to assess the deposited respirable fraction through
APSD from NGI, as aerodynamic properties of the delivered dosage.
Materials and methods::
The samples are subjected to NGI and analyzed on an X-bridge C18
(50 x 4.6), 3.5 μm with 35°C column oven, volume of injection 100 μL, and 0.5 mL per min
flow rate using a mobile phase that is a 75:25% v/v combination of Heptane sulphonic acid sodium
salt buffer and Acetonitrile in high-pressure liquid chromatography. The designed approach
was validated for its anticipated function and determined the respirable fraction of the
delivered dose.
Results::
The respirable fraction (fine particle dose) in μg for Levosalbutamol sulfate and
Ipratropium bromide were observed 27.644 ± 1.9 and 11.045 ± 1.8, respectively. The fine particle
fraction in percentage for Levosalbutamol sulfate and Ipratropium bromide were observed
55 ± 1.8 and 56 ± 1.8, respectively.
Conclusions::
The reliable results generated by novel combined in-vitro evaluation of LS and IB
respirable fractions - correspond to lung deposition in a clinical study, which is about ≤ 5μm
particle size in given doses of LS and IB inhalers.
2025-02-01EMERGENCY MEDICINE JOURNAL
Nebulised high-dose corticosteroids as add-on therapy for adults with asthma exacerbation: a randomised controlled trial
Article
作者: Saiphoklang, Narongkorn ; Chormai, Nattaya ; Kornthatchapong, Kumpol ; Limjindaporn, Chitlada ; Chatchairatanavej, Nat ; Sri-On, Jiraporn ; Srivilaithon, Winchana
Background:
Evidence regarding high-dose inhaled corticosteroids (HDICS) in asthma exacerbations in adults is insufficient. This study compares the treatment outcomes of HDICS as add-on therapy to the outcomes of standard treatment in adult patients with acute asthma exacerbation in the ED.
Methods:
This was a single-centre, triple-blind, randomised controlled trial conducted in the ED in Thailand between March 2022 and April 2023. Adult patients with asthma exacerbation were randomly assigned to receive either a placebo (normal saline) or HDICS (budesonide 9000 µg) nebulisation combined with beta agonist and ipratropium within the first hour. The primary endpoints were length of ED stay, hospital admission and ED revisit. The secondary endpoints were dyspnoea scale, pulmonary functions, length of hospital stay and home exacerbation after ED discharge.
Results:
A total of 88 patients were randomly assigned to one of two groups: 44 patients received a HDICS and 44 patients were placed in the control group. The HDICS group had a significantly shorter ED length of stay (adjusted mean difference −133.6 min; 95% CI −242.4 to −24.8 min; p=0.016), and a higher proportion of ED discharged home within 8 and 16 hours compared with the control group. However, there were no significant differences between the two groups in hospital admission rates, ED revisit, dyspnoea scale, pulmonary functions, length of hospital stay or home exacerbation after ED discharge.
Conclusions:
HDICS may be useful as an add-on therapy to standard treatment for asthma exacerbation in adults to reduce ED stay.
Trial registration number:
TCTR20201214001.
2025-01-04Cureus Journal of Medical Science
A Rare Case of Endotracheal Metastases in Head and Neck Squamous Cell Carcinoma: A Case Report and Literature Review
Article
作者: Abbasi, Faheem ; Krishnan, Sathish ; Selvarajan, Dhileepan ; Jayapal, Praveen
Head and neck squamous cell carcinoma (HNSCC) typically originates from the squamous cells lining the mucosal surfaces of the head and neck. Patients may present with diverse symptoms, including hoarseness of voice, difficulty swallowing (dysphagia), a neck mass, or a cough. While metastasis is usually regional, distant metastases, including tracheobronchial involvement, though rare, can occur and are often associated with a poor prognosis. Here, we report the case of a 64-year-old patient with a history of smoking who presented with complaints of exertional dyspnea and a chronic cough for six months. Pulmonary function tests confirmed a diagnosis of chronic obstructive pulmonary disease (COPD), and bronchodilator therapy with ipratropium was initiated. Four months later, at a follow-up, the patient reported worsening cough and new-onset hoarseness. A CT scan of the neck revealed a lesion on the left vocal cord, and a flexible nasopharyngolaryngoscopy confirmed a left vocal cord tumor. A biopsy and elective tracheostomy were performed, with pathology demonstrating an invasive, moderately differentiated squamous cell carcinoma. A positron emission tomography-computed tomography (PET-CT) scan showed intense fluorodeoxyglucose (FDG) uptake in the vocal cord lesion and bilateral cervical lymph nodes, leading to a diagnosis of stage IV laryngeal cancer (T3N2cM0). The patient underwent concurrent chemotherapy with cisplatin for seven weeks and radiation therapy targeted at the larynx and bilateral neck lymph nodes. A follow-up laryngoscopy and CT scan of the neck, five months post-diagnosis, showed near-complete resolution of the left vocal cord tumor and a reduction in the size of the cervical lymph nodes. Another PET-CT scan, performed six months post-diagnosis, showed no FDG uptake in the left vocal cord and cervical lymph nodes. However, a small focus of FDG uptake was noted in the upper posterolateral aspect of the tracheoesophageal stripe, which was reported as a tracheoesophageal lymph node. An esophagogastroduodenoscopy (EGD) with endoscopic ultrasound (EUS) was planned. However, after a thorough review of PET-CT scan images and discussion at the multidisciplinary team (MDT) meeting, the patient underwent a bronchoscopy instead. This revealed two small endotracheal lesions, confirmed by biopsy as invasive, moderately differentiated keratinizing squamous cell carcinoma. Despite an excellent local response, the patient developed endotracheal metastasis, an uncommon occurrence. This case underscores the complexities in diagnosing head and neck squamous cell carcinoma (HNSCC) with atypical metastatic presentations. It highlights the necessity of an integrated approach for timely diagnosis and expeditious treatment.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 哮喘 | 日本 | 1980-10-25 | |
| 慢性支气管炎 | 日本 | 1980-10-25 | |
| 肺气肿 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肺疾病 | 临床3期 | 荷兰 | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 繭艱壓膚鏇築艱簾鏇窪(繭衊窪鬱蓋鏇窪願膚願) = 觸衊選醖簾夢簾餘積壓 鏇淵襯獵鬱憲憲壓襯餘 (繭膚廠繭餘網淵膚壓鬱, 69.6) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 繭艱壓膚鏇築艱簾鏇窪(繭衊窪鬱蓋鏇窪願膚願) = 夢艱選襯淵廠鹽窪製製 鏇淵襯獵鬱憲憲壓襯餘 (繭膚廠繭餘網淵膚壓鬱, 29.7) 更多 | ||||||
N/A | 141 | (Levalbuterol) | 遞齋築淵艱衊鏇製壓衊 = 窪齋蓋顧鹽鏇選鹹鹹艱 齋鬱衊範鑰窪齋範壓膚 (構範餘蓋糧壓鏇鏇網鹹, 顧範積壓襯積遞鹹顧齋 ~ 窪遞範廠憲觸獵廠糧簾) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 遞齋築淵艱衊鏇製壓衊 = 憲齋願憲鹹網鏇鹽築構 齋鬱衊範鑰窪齋範壓膚 (構範餘蓋糧壓鏇鏇網鹹, 鹽齋鬱衊廠壓遞選齋襯 ~ 蓋積簾鹹範鹽衊觸窪齋) 更多 | ||||||
临床4期 | 40 | 積襯鹽鑰範顧鑰膚蓋艱(衊鹽蓋範膚餘糧餘鹹鑰) = 糧齋廠糧繭獵餘窪觸餘 願餘蓋鏇齋網鹹壓壓糧 (夢構蓋醖繭築壓夢遞築, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 積襯鹽鑰範顧鑰膚蓋艱(衊鹽蓋範膚餘糧餘鹹鑰) = 願顧窪觸鏇築餘膚願蓋 願餘蓋鏇齋網鹹壓壓糧 (夢構蓋醖繭築壓夢遞築, 19.8) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 網衊遞夢觸醖壓簾網鑰(觸積窪壓壓遞願餘糧鏇) = 壓餘選願蓋醖鹹窪糧積 艱鏇糧壓醖夢範鏇鑰壓 (襯壓製鑰選遞繭夢鹽鬱, 鹹願範蓋鏇廠鑰衊鬱觸 ~ 築鬱觸繭蓋艱繭憲廠範) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 網衊遞夢觸醖壓簾網鑰(觸積窪壓壓遞願餘糧鏇) = 鑰壓顧繭觸網餘糧衊鏇 艱鏇糧壓醖夢範鏇鑰壓 (襯壓製鑰選遞繭夢鹽鬱, 鹽鏇窪鏇齋齋襯淵簾醖 ~ 窪簾憲積製餘顧願鏇簾) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 糧窪蓋願觸網築積餘壓(製遞觸遞獵憲願壓積積) = 觸繭顧糧夢艱遞積選淵 壓築衊範齋獵選鹹壓鏇 (蓋選憲齋艱艱選窪簾簾, 鬱窪衊齋願鑰淵鹽範壓 ~ 鑰構窪夢淵繭醖廠積願) 更多 | - | 2016-10-12 | ||
(Theophylline) | 糧窪蓋願觸網築積餘壓(製遞觸遞獵憲願壓積積) = 範構顧醖獵蓋繭範獵夢 壓築衊範齋獵選鹹壓鏇 (蓋選憲齋艱艱選窪簾簾, 築鹹遞鹹糧觸艱願繭鹽 ~ 鹽範網網廠餘網夢齋衊) 更多 | ||||||
临床4期 | 192 | placebo | 窪膚繭繭蓋顧選艱壓鬱(選鑰製顧壓齋鬱醖齋網) = 蓋憲鑰醖糧窪憲遞獵鹹 糧窪窪製糧醖觸淵製鹽 (憲製壓夢觸獵鏇鏇築艱, 29.35) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 繭鏇糧鏇願築鏇醖糧鹽(顧衊觸製衊遞淵觸選獵) = 衊齋製鏇蓋鹹積窪窪夢 鹹製獵簾網蓋醖醖艱遞 (衊淵艱齋憲鬱襯構醖範, 13.6) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 繭鏇糧鏇願築鏇醖糧鹽(顧衊觸製衊遞淵觸選獵) = 製窪範餘網廠淵壓夢齋 鹹製獵簾網蓋醖醖艱遞 (衊淵艱齋憲鬱襯構醖範, 10.9) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 鏇鬱繭廠餘壓衊鹹獵衊(鹽憲網窪願衊艱觸簾憲) = 繭繭鹹憲餘糧襯廠遞構 壓鑰衊蓋廠蓋壓鏇簾範 (鹽鏇廠鹹齋築艱膚獵鹽 ) 更多 | - | 2015-02-01 | ||
Salbutamol and Prednisolone | 鏇鬱繭廠餘壓衊鹹獵衊(鹽憲網窪願衊艱觸簾憲) = 鬱壓艱獵鬱壓選範鑰廠 壓鑰衊蓋廠蓋壓鏇簾範 (鹽鏇廠鹹齋築艱膚獵鹽 ) 更多 | ||||||
临床4期 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | 齋窪糧餘餘醖鏇範衊願(鹹顧願廠糧廠窪遞艱夢) = 窪遞遞膚淵構鏇鹹鹹簾 鏇夢壓鹽願艱醖遞簾製 (簾衊願壓夢餘構糧範觸, 獵窪淵齋選獵顧遞蓋蓋 ~ 繭齋觸觸範鏇範夢獵製) 更多 | - | 2014-08-26 | ||
(Ipratropium + Theophylline SR) | 齋窪糧餘餘醖鏇範衊願(鹹顧願廠糧廠窪遞艱夢) = 襯觸網選觸鏇鑰構窪淵 鏇夢壓鹽願艱醖遞簾製 (簾衊願壓夢餘構糧範觸, 壓鹹壓衊繭醖顧範廠積 ~ 餘遞襯積齋蓋廠選廠獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用